Tharimmune Shares Surge 45.7% on FDA 505(b)(2) Nod and BlackRock Stake

Introduction to THARIMMUNE INC

Tharimmune Inc (NASDAQ: THAR) is a clinical-stage biotechnology company based in Red Bank, New Jersey. The firm develops therapeutic candidates in immunology, inflammation, and oncology. Its lead asset, TH104, utilizes a transmucosal buccal film formulation and is progressing through a 505(b)(2) regulatory pathway for temporary prophylaxis against respiratory and nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids. The broader pipeline includes TH104 for chronic pruritus in primary biliary cholangitis (PBC) and TH023 for autoimmune indications, as well as an early-stage multispecific biologics program leveraging proprietary EpiClick™ technology targeting solid tumors.

Corporate Structure and Leadership

Tharimmune operates with a team of 11–50 employees. Sireesh Appajosyula has served as chief executive officer since June 2025, previously holding the position of chief operating officer from July 2023 and serving as a board member since July 2021. His background includes senior roles at 9 Meters Biopharma, Salix Pharmaceuticals (Nasdaq: SLXP), Amgen, and Sanofi. The company has a license agreement with OmniAb, Inc., which provides access to an antibody discovery platform to support its multispecific biologics efforts.

Biotechnology by Louis Reed

Recent Developments and News

• On November 3, 2025, shares of THARIMMUNE INC closed at $4.2991, reflecting a 45.73% increase from the previous trading session, with a trading volume of 2,330,550 shares on the NASDAQ.
• In May 2024, Tharimmune announced that the U.S. Food and Drug Administration (FDA) confirmed no additional clinical trials are required before submitting a 505(b)(2) New Drug Application (NDA) for TH104 in the prophylaxis indication.
• On October 17, 2025, Tharimmune filed a Schedule 13G with the SEC, reporting that BlackRock, Inc. beneficially owns 663,882 shares, which represent 9.8% of the common stock.
• Also on October 17, 2025, the company submitted a Form S-3 registration statement to enable future offerings of equity and debt securities, and a Form S-8 to register 1,207,398 additional shares under its 2023 Omnibus Equity Incentive Plan.

Financial and Strategic Analysis

Tharimmune’s trading activity on November 3, 2025, may be correlated with investor interest following the FDA’s confirmation of the 505(b)(2) pathway and the reported stake by BlackRock, Inc. The Form S-3 shelf registration suggests the potential for raising capital to support ongoing activities, such as Chemistry, Manufacturing, and Controls (CMC) optimization, Phase 2 readiness in the U.S. and EU, and stability studies planned through 2026. The Form S-8 filing indicates a strategy to utilize equity incentives to align employee interests with those of shareholders, reflecting the operational considerations of a small, innovation-focused enterprise reliant on specialized talent.

Market Position and Industry Context

Within the biotechnology sector, Tharimmune targets niche indications with significant unmet medical needs, such as opioid-induced respiratory depression and PBC-associated pruritus. Its 505(b)(2) strategy may reduce development timelines, and its EpiClick™-driven multispecific platform positions the company in the immuno-oncology landscape, alongside peers focused on PD-1, HER2, and HER3 targets. Partnerships, such as the one with OmniAb, and the leadership's experience in biotechnology and pharmaceutical commercialization are key factors in advancing Tharimmune’s clinical-stage research toward future regulatory milestones.

tl;dr

On November 3, 2025, Tharimmune’s stock increased by 45.73% to $4.2991 on high trading volume after the FDA confirmed a 505(b)(2) NDA pathway for TH104 without requiring further trials. On October 17, 2025, BlackRock disclosed a 9.8% ownership stake via Schedule 13G, and Tharimmune filed Form S-3 and S-8 statements to establish capital-raising flexibility and expand its equity incentive plan. Upcoming milestones include the completion of stability data in 2025/2026 and an NDA filing for TH104 in 2026.